Final NHS nod for Janssen’s Imbruvica

Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.

• Source: Pharmatimes
• 530
• February 2, 2018